Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 41 to 50 of 297

TitleTypeExpected publication date
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]Technology appraisal guidanceTBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]Technology appraisal guidance
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]Technology appraisal guidance
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Technology appraisal guidanceTBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]Technology appraisal guidanceTBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment ID6370Technology appraisal guidanceTBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]Technology appraisal guidanceTBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]Technology appraisal guidanceTBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]Technology appraisal guidance
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All